Pasar al contenido principal

Conexión rápida

CPHI China 2023

Join us and explore how we can accelerate access
to affordable medicines together.

Meet our team at
CPHI China, 2023

19th-21st June 2023
Shanghai New International Expo Center, China
Booth #N3D99
Contact Us

Our Team at
CPHI China

About CPHI China

CPHI China is Asia's premier pharma event that brings together leading pharma experts from across the end-to-end pharma supply chain. The event offers a one-stop shop for the pharmaceutical industry, allowing attendees to access a vast array of pharmaceutical ingredients, machinery, laboratory equipment, environmental protection, pharma packaging, and processing solutions - all conveniently located under one roof.

With thousands of local and international exhibitors in attendance, this year's edition promises to be the best one yet. Attendees can source cutting-edge solutions, and attend a range of presentations, forums, showcases, and other industry events to expand their knowledge and expertise.

The event offers more flexibility and pre-connect opportunities to attendees who want to network with peers face-to-face to connect with potential business prospects and collaborate to overcome challenges. With a jam-packed conference planned across 3 days, attendees can learn from experts, leaders, and fresh new voices, staying ahead of all pharma trends.

Join us this June, where the show will return for the first time in three years, and be part of this exciting event that offers limitless possibilities for professionals looking to expand their business in China's booming pharma market!

About Dr.Reddy’s API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.


Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.


Our Achievement

Manufacturing Location

Dr. Reddy’s API  Manufacturing Locations


© 2023 Dr. Reddy’s Laboratories Ltd. All rights reserved.


Ninguna información en este catálogo, incluida cualquier referencia a cualquier producto o servicio, constituye una oferta de venta, ni debe interpretarse como representación de una oferta de venta. Los productos protegidos por patentes válidas no se ofrecen ni se suministran para uso comercial. Sin embargo, las cantidades de investigación de dichos productos pueden ofrecerse con el fin de presentaciones reglamentarias, siempre que existan dichas exenciones reglamentarias. Los compradores deben realizar una evaluación independiente del escenario de la patente para sus respectivos mercados y serán responsables de todas las responsabilidades relacionadas con la patente. Los productos protegidos por patentes válidas en la India no están disponibles para uso comercial, pero estarían disponibles para los fines de la Sección 107A.